πŸ«€ 2026 ACC/AHA Dyslipidemia CPG Navigator

Evidence-based Β· Click (?) for CPG references

1
Demographics
πŸ‘€
Who is the patient?
β–Ό
PREVENT equations are validated for ages 30–79. For ages 18–29, use 30-year risk estimate.Section 2.1.1, Table 2βœ•
PREVENT uses sex-specific coefficients. Sex assigned at birth is used (not gender identity) for risk equations.Section 2.1.1, PREVENT derivation cohortβœ•
South Asian ancestry is a risk enhancer that may shift risk category upward (1.5–2Γ— ASCVD risk at same risk factor levels).Section 4.2, Table 3 β€” Risk Enhancersβœ•
Statins and most nonstatins are contraindicated during pregnancy and lactation. Discontinue before planned conception.Section 4.2.8.1 β€” Pregnancy & Lactationβœ•
2
Medical History
πŸ«€
Cardiovascular & Metabolic Conditions
β–Ό
ASCVD includes MI, stroke, PAD, coronary revascularization, etc. Very high-risk: recurrent ASCVD events, or ASCVD + multiple high-risk conditions. Post-ACS ≀12 months is highest risk.Section 2.2 β€” Definitions; Section 4.2.5 β€” Secondary Preventionβœ•
Diabetes is a major ASCVD risk equivalent. For age 40–75 with LDL-C β‰₯70, start moderate- or high-intensity statin regardless of baseline LDL-C. Duration β‰₯20 years is a risk enhancer.Section 4.2.6 β€” Diabetesβœ•
CKD stage 3–4 is a risk enhancer. Treat with moderate-intensity statin + ezetimibe. Do NOT initiate statin in dialysis patients (unless already on statin).Section 4.2.8.4 β€” CKDβœ•
HIV is a risk enhancer. Moderate- or high-intensity statin recommended. Prefer pravastatin, rosuvastatin, pitavastatin (non-CYP3A4) to avoid ARV interactions.Section 4.2.8.6 β€” HIVβœ•
⚑
Risk Enhancers ?
β–Ό
Risk enhancers modify risk category upward and influence treatment intensity, especially in borderline and intermediate risk. They do NOT have COR/LOE themselves but inform shared decision-making.Section 4.2.2 β€” Risk Enhancers (Table 3)βœ•
First-degree male <55 yr or female <65 yr at ASCVD onset. Modifies risk category upward.Table 3βœ•
β‰₯3 of: elevated waist, TG β‰₯150, low HDL-C, BP β‰₯130/85, elevated glucose.Table 3βœ•
Preeclampsia increases lifetime ASCVD risk. Consider earlier screening and treatment.Table 3; Section 4.2.8.2βœ•
Menopause before age 40 is a risk enhancer.Table 3βœ•
"In adults with elevated Lp(a), optimize LDL-C management to lower goals regardless of baseline LDL-C."Section 4.2.10 β€” Elevated Lp(a)βœ•
"Lp(a) β‰₯250 nmol/L is associated with approximately 2-fold increased ASCVD risk."Section 4.2.10βœ•
PAD is ASCVD-equivalent. Treat with high-intensity statin, goal LDL-C <70 mg/dL.Section 4.2.5βœ•
South Asian ancestry carries ~1.5–2Γ— ASCVD risk at the same traditional risk factor levels and is a recognized risk enhancer.Table 3; Section 4.2.2βœ•
LDL-C β‰₯160 mg/dL despite 3–6 months of intensive lifestyle modification is a risk enhancer, especially in young adults.Table 3βœ•
CAC β‰₯100 or β‰₯75th percentile for age/sex/race effectively reclassifies to high risk and warrants high-intensity statin.Section 4.2.2.4 β€” CACβœ•
3
Basic Labs
πŸ§ͺ
Lipid Profile
β–Ό
Primary treatment target. Measured directly or by Friedewald/Martin-Hopkins calculation. Non-fasting acceptable unless TG β‰₯400 or FH suspected.Section 3.3 β€” LDL-C Measurementβœ•
Fasting preferred for TG β‰₯400. TG 150–499: lifestyle + statin. TG β‰₯500: consider fibrate for pancreatitis prevention. TG β‰₯1000: urgent fibrate.Section 4.2.9 β€” Hypertriglyceridemiaβœ•
If on statin, estimate untreated LDL-C for initial risk classification. Untreated LDL-C β‰ˆ treated LDL-C Γ— 2 for high-intensity or Γ— 1.4 for moderate-intensity.Section 3.5 β€” Estimating baseline LDL-Cβœ•
4
Advanced Labs
πŸ”¬
Biomarkers
β–Ό
ApoB may be preferred as the primary marker for screening, diagnosis, and management (COR IIa). Alternative target: ApoB <80 mg/dL (high risk) or <65 mg/dL (very high risk).Section 3.4 β€” ApoBβœ•
COR I: Measure Lp(a) at least once in all adults. β‰₯125 nmol/L (β‰ˆ50 mg/dL) is elevated. β‰₯250 nmol/L β‰ˆ 2-fold ASCVD risk. Do not repeat unless considering therapy.Section 3.6 β€” Lp(a) Measurementβœ•
Required for PREVENT equations. eGFR should be re-checked within 3 months of statin initiation. Values <60 indicate CKD β€” use CKD-EPI equation.Section 3.7 β€” CKM Healthβœ•
5
Clinical Exam
🩺
Vitals, Habits & Symptoms
β–Ό
Used in PREVENT equations. SBP + antihypertensive therapy status are both required. Target BP <130/80 in most patients with dyslipidemia.Section 3.7.1βœ•
BMI is a PREVENT equation variable. Waist circumference adds metabolic syndrome assessment. Lifestyle goal: BMI 18.5–24.9, weight loss 5–10% if overweight/obese.Section 4.1 β€” Lifestyleβœ•
Smoking is a major ASCVD risk factor. Assessed in PREVENT equations. Counseling and cessation resources should be offered (COR I).Section 4.1 β€” Smoking Cessationβœ•
Routine CK monitoring in asymptomatic patients is NOT recommended (COR III: No Benefit). SAMS workup: rule out other causes, trial off 2–4 wk, rechallenge, switch to hydrophilic statin, then nonstatin if needed.Section 4.2.11 β€” SAMSβœ•
6
PREVENT Risk
πŸ“Š
AHA PREVENTβ„’ Risk Score ?
β–Ό
PREVENT equations replace PCE/ACC/AHA Pooled Cohort Equations. Race-free, CKM-integrated. Validated in US adults aged 30–79. Uses age, sex, TC, HDL-C, SBP, BP treatment, diabetes, smoking, eGFR, BMI.Section 2.1.1; Khan SS et al. Circulation 2024;149:1606–1635βœ•
πŸ”„ Calculate PREVENT Risk
7
Decision Outputs
🎯
Risk Category & LDL-C Goals
β–Ό
🫁
CAC Scoring
β–Ό
πŸ₯—
Lifestyle Plan
β–Ό
πŸ’Š
Pharmacotherapy
β–Ό
πŸ‘₯
Special Populations
β–Ό
πŸ“ˆ
Triglyceride Check
β–Ό
⚠️
Drug Interactions
β–Ό
πŸ“…
Monitoring
β–Ό
πŸ“‹
Clinical Summary
β–Ό
πŸ“„ Generate Summary

2026 ACC/AHA Guideline on Management of Dyslipidemia Β· For clinical decision support Β· Individualize care